MYLD - ETF AI Analysis
Top Page
Cambria Micro and SmallCap Shareholder Yield ETF (MYLD)
MYLD’s rating suggests it is a reasonably solid but not top-tier micro and small-cap ETF, with a mix of strong and more challenged holdings. Standout positions like Riley Exploration Permian and Slide Insurance Holdings support the fund’s quality through strong financial performance and attractive valuations, while names such as Harley-Davidson and Nu Skin introduce pressure due to declining revenues, leverage, and operational challenges. The main risk factor is the ETF’s focus on smaller companies, where individual business or execution issues can have a bigger impact on overall performance.
MYLD vs. SPDR S&P 500 ETF (SPY)
- AUM
- 53.83M
- Region
- North America
- Expense Ratio
- 0.62%
- Beta
- 0.83
- Issuer
- Cambria
- Inception Date
- Jan 04, 2024
- Dividend Yield
- 2.33%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
MYLD Summary
MYLD is the Cambria Micro and SmallCap Shareholder Yield ETF, focusing on very small U.S. companies that return cash to investors through dividends and buybacks. It doesn’t track a traditional index, but follows a theme of smaller, shareholder-friendly businesses across many sectors like financials, consumer companies, and industrials. Well-known names in the fund include Harley-Davidson and Boston Beer. Investors might consider MYLD for growth potential and diversification beyond large, well-known stocks. However, smaller companies can be more volatile, so the price of this ETF can move up and down more sharply than the overall market.
How much will it cost me?
This ETF has an expense ratio of 0.62%, which means you’ll pay about $6.20 per year for every $1,000 you invest. That’s higher than the average ETF because it’s actively managed and focuses on a specialized group of micro- and small-cap companies, which typically costs more to research and manage.
What would affect this ETF?
MYLD could benefit if the U.S. economy stays healthy, consumer spending remains strong, and smaller companies in areas like financials, consumer cyclical, and industrials keep growing and returning cash to shareholders through dividends and buybacks. On the downside, higher interest rates, an economic slowdown that hurts small U.S. businesses, or sector-specific problems in areas like energy, health care, or consumer brands such as Harley-Davidson and Boston Beer could weigh on the fund’s performance.
MYLD Top 10 Holdings
MYLD leans into U.S. micro and small caps, with financials and consumer names steering the ship. Riley Exploration Permian has been a key engine, rising steadily on strong energy fundamentals, while Slide Insurance and Harley-Davidson add more momentum from the financial and consumer cyclical side. Pacira Pharmaceuticals and Pediatrix Medical Group keep health care exposure humming, though their mixed signals and volatility can tug at returns. Boston Beer, meanwhile, feels more like a slow sipper than a growth rocket, slightly holding back the fund’s overall pace.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 PCRX | Pacira Pharmaceuticals | 1.40% | $752.07K | $1.46B | 72.65% | 69Neutral |
 CARS | Cars | 1.36% | $730.30K | $695.21M | 20.38% | 68Neutral |
 SAM | Boston Beer | 1.33% | $717.20K | $2.24B | 10.62% | 68Neutral |
 HOG | Harley-Davidson | 1.28% | $689.03K | $3.30B | 29.91% | 60Neutral |
 DXC | DXC Technology | 1.25% | $672.53K | $2.31B | 8.94% | 62Neutral |
 APOG | Apogee | 1.25% | $672.45K | $956.39M | 32.40% | 64Neutral |
 MD | Pediatrix Medical Group | 1.21% | $651.22K | $2.44B | 43.40% | 76Outperform |
 ACCO | ACCO Brands | 1.20% | $645.25K | $467.25M | 45.40% | 59Neutral |
 LCII | LCI Industries | 1.19% | $638.74K | $2.38B | -9.44% | 79Outperform |
 OSPN | OneSpan | 1.18% | $636.79K | $796.56M | 76.97% | 71Outperform |
MYLD Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MYLD, the sentiment is Neutral. The current price of 32.86 is below the 20-day moving average (MA) of 33.14, below the 50-day MA of 32.89, and above the 200-day MA of 30.85, indicating a neutral trend. The MACD of 0.22 indicates Positive momentum. The RSI at 46.85 is Neutral, neither overbought nor oversold. The STOCH value of 30.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MYLD.
MYLD Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| MYLD | $32.86 | $36.00(9.56% Upside) | $53.83M | 0.62% | 68Neutral |
 OASC | $32.71 | $41.48(26.81% Upside) | $97.22M | 0.69% | 68Neutral |
 POMG | $26.58 | $33.53(26.13% Upside) | $69.70M | 0.68% | 66Neutral |
 BCSM | $24.30 | $30.93(27.32% Upside) | $35.82M | 0.75% | 58Neutral |
 IVSS | $29.83 | $36.74(23.17% Upside) | $29.97M | 0.59% | 69Neutral |
 BRSM | $24.91 | $30.21(21.29% Upside) | $26.79M | 0.38% | 66Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MYLD | Cambria Micro and SmallCap Shareholder Yield ETF | 32.86 | 7.83 | 31.30% | |
| OASC | OneAscent Small Cap Core ETF | 32.71 | 3.99 | 13.88% | |
| POMG | PRIMECAP Odyssey Discovery ETF | 26.58 | 1.06 | 4.15% | |
| BCSM | Baron SMID Cap ETF | 24.30 | -0.01 | -0.03% | |
| IVSS | Applied Finance IVS US SMID ETF | 29.83 | 4.61 | 18.28% | |
| BRSM | MFS Blended Research Small-Mid Cap ETF | 24.91 | -0.13 | -0.51% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.